Background: The method described provides a rational means for determining whether to institute chronic anticoagulation to prevent stroke in patients with chronic atrial fibrillation under a variety of clinical circumstances.
T here are a number of circumstances involving patients at risk for stroke due to cerebrovascular disease or cardiogenic embolism in which the potential risks and benefits of chronic anticoagulation are sufficiently close as to render clinical decision making quite difficult. In part this reflects the fact that the risks and benefits of anticoagulation have not yet been completely defined at the population level, an issue that can only be addressed by further study. However, in part it reflects uncertainties intrinsic to individual patients. Dealing with these uncertainties in a rational, quantitative fashion will be the focus of this article. Specifically, I will discuss anticoagulation in patients with stroke or transient ischemic attack and chronic atrial fibrillation in whom the relation of the rhythm abnormality to the ischemic event is uncertain or in whom the nature of the ischemic event itself is uncertain (ie, microvascular or large-vessel distribution). I will also discuss anticoagulation of patients with atrial fibrillation in the absence of stroke or transient ischemic attack. Although a quantitative approach is used, many uncertainties remain, and the results should be used as a guide to decision making and not applied in a formulaic fashion.
The general approach to be used makes use of the concept of expected value, which is equal to the product of the actual value of the end point and the likelihood of the end point. Thus, the expected value of a 99:1 prospect at the horse races that pays $100 to win is (0.01)($100)=$1. The concept of expected value provides a way of arriving at the value of an uncertain end point in a rational fashion. The actual value of the end point in the context of this article is to be determined by the patient (see "Appendix'). The likelihood of the end point can be ascertained from existing data. Anticoagulation decisions in patients at risk for cardiogenic embolic stroke have been discussed previously in a decision analytic framework,' but the method used failed to include an explicit assessment of the value system of the patient, something repeatedly shown to be very important2-4; it also involved cumbersome calculations requiring the use of a decision-making computer program. The method used in the present article is intended to be easily usable by clinicians with access only to the data included herein. (Table 2) .
For the patient with stroke definitely due to cardiogenic embolism, the 1-year expected positive value of chronic anticoagulation, 0.13VS, is clearly considerably higher than the 1-year expected negative value of chronic anticoagulation, 0.043VD to 0.05VD, as long as the patient feels that stroke is a very serious event with a negative value close to that of death. However, these values are close enough that an explicit assessment of the patient's values is warranted. This can often be done in a relatively informal manner, but in many instances a formal standard gamble discussion will be necessary (see "Appendix"). In my experience with standard gamble discussions in this context, patients who place a high value on intact intellectual function and physical independence will often conclude that stroke has 80% of the disvalue of death; at the other extreme, patients may conclude that stroke has as little as 25% of the disvalue of death. Assuming the 25% figure, the expected positive value (EV+) of anticoagulation would be (0. (Table 1 ). This assumes of course that the risk of fatal hemorrhage is evenly distributed over time; limited data suggest that it is.13 Possible Cardiac or Artery-to-Artery Thromboembolism It is often difficult to determine in a stroke patient with atrial fibrillation whether the embolus came from the heart or from a site of atheromatous disease in the neck or the aorta. Carotid duplex or angiographic evidence of carotid thrombus in situ or, to a lesser extent, ulceration; a stuttering, waxing and waning, progressive course17 (but see Reference 18); and multiple events in a single vascular territory, particularly the posterior circulation, favor artery-to-artery thromboembolism. Evidence of multiple events in different cerebral arterial distributions; stroke in conjunction with hematuria (presumably reflecting renal embolism19); and hemorrhagic infarction6 favor cardiogenic embolism.
In the final analysis, however, in an elderly patient with a single cerebrovascular event and carotid stenosis without in situ thrombus, it is generally not possible to determine the origin of the cerebral embolus with certainty. Instead, this risk must be calculated on the basis of probabilities. In patients with chronic atrial fibrillation, the annual risk of stroke attributable to the atrial fibrillation is 3.5%.2O I will assume that the annual stroke risk in the distribution of a particular carotid is 45% of this, which is the fraction of total cerebral blood greater than 20% and that chronic anticoagulation is of no value in preventing recurrent stroke due to arteryto-artery thromboembolism; neither hypothesis has been adequately tested. In this case, even if the patient valued stroke very negatively (eg, Vs=0.8VD), the expected positive value of anticoagulation (EV+=(0.8) (0.044)VD=0.035VD) would be less than the expected negative value of anticoagulation, 0.05VD, and a full year of anticoagulation could not be justified.
Possible Lacunar Infarction
There is a general consensus that lacunar infarction is almost always due to intrinsic microvascular disease and is uncommonly embolic in origin.28 Thus, if a patient in chronic atrial fibrillation experiences a lacunar stroke, it is safe to say that the stroke was unlikely to be due to cardiogenic embolism, and the conditions of the clinical decision are those of the patient with chronic asymptomatic atrial fibrillation (see below). Unfortunately, situations frequently arise in which it is not possible to be sure whether the patient has had a lacunar or a large-vessel event. This is because of the fact that clinical discrimination between the two types of stroke is frequently inadequate, particularly when there is a mild neurological deficit, and the fact that computed tomography detects only 40% of lacunes and 70% of large-vessel infarcts29 and magnetic resonance imaging detects about 80% of lacunes3031 but is probably not much better than computed tomography at detecting patient of death. 1-year expected positive value=(1-year probability of stroke)(probability that stroke is cardiogenic)(efficacy of warfarin)Vs. 1-year expected negative value=(1-year probability of fatal hemorrhage)VD+(probability of nonfatal intracranial hemorrhage)Vs. Assumed efficacy of warfarin=65%; probability of nonfatal intracranial hemorrhage is assumed to be 0. 33 In older studies of chronic anticoagulation of patients with ischemic heart disease it was 0.6%.13 I will assume a rate of 0.5% for this analysis. The expected negative value of warfarin would then be 0.0063VD, taking into account morbidity from nonfatal intracranial hemorrhage. The net expected value of anticoagulation for 1 year would then be (0.026-0.0063)VD=0.0197VD, providing a strong rationale for chronic anticoagulation. At the other extreme, patients may consider stroke to have only 25% of the disvalue of death, yielding an expected positive value of anticoagulation of (0.25)(0.0325)VD= 0.008VD. This is only 1.48 times the expected negative value of anticoagulation (0.008/0.0054), and if the risk of fatal hemorrhage with anticoagulation were suspected to be much higher than usual, the net expected value of chronic anticoagulation would become negative. In the patient with a history of stroke, however remote, the annual risk of fatal hemorrhage, as noted above, may be 4%, thus contraindicating anticoagulation in all stroke patients after the first year (but see sensitivity analysis, Table 2 ). Further studies are necessary to refine our ability to predict fatal intracranial hemorrhage in anticoagulated patients.
I have assumed an annual stroke risk of 5% in patients with chronic atrial fibrillation without a history of stroke or within the next few days (point to the bottom path). However, there is a radical treatment that could absolutely prevent you from having a stroke (point to upper fork of top path). Unfortunately, this treatment carries with it a risk of death (point to lower fork of top path). What is the minimum chance of a cure that you would have to have to accept the radical treatment? I'm going to put some numbers in here and I want you to tell me when it seems like it's a toss-up -the two paths seem about the same. (Write in 50 on both forks of upper path). Here, if you accept the treatment, you have a 50-50 chance of a cure-good health without a stroke-but also a 50-50 chance of dying. Over here (point to lower path), you will definitely have a stroke. Which path would you choose? Remember, these numbers do not apply directly to your situation; however, they will help me to advise you whether to take warfarin, which does involve accepting some risk of dying in order to prevent stroke. (Substitute in successively higher or lower numbers in 10% to 20% increments until the patient understands the problem and settles on a set of numbers. The percentages on the two upper branches must always add up to 100. The likelihood of death at which the patient is ambivalent about the radical treatment constitutes the best estimate of his valuation of stroke relative to death.) This approach to estimating the disvalue of stroke makes some simplifying assumptions. First, it treats stroke as a permanent state, as opposed to an event followed by some degree of recovery and return to at least some aspects of normal life. Second, it treats all strokes as equal, when in fact the impact of minor and major stroke is obviously quite different. Third, it leaves to the patient the task of estimating the long-term personal ramifications of nonfatal events that occur during the treatment (or nontreatment) period. Other investigators have used Markov and related models to deal with these problems in various contexts.1,3738 These models in essence calculate expected values for each of the remaining months of the patient's life, entering into the calculation the probability that the patient will experience a change in state, eg, from health to stroke, stroke to death, or health to death, in any particular month. Arbitrary disvalues are attached to the various states, eg, major stroke and minor stroke, and a discount factor is used to account for the fact that events that occur or states that exist at some time in the future have less value, or disvalue, than when they develop immediately. The net result is an estimate of the value of a particular strategy measured in quality-adjusted life expectancy. The major source of appeal of this approach is that the product, qualityadjusted life years, is easily comprehended by the physician and easily used as a "common currency" of decision making. I have not used this approach because obtaining the patient's estimates of the relative disvalue of major stroke, minor stroke, and expected states of recovery from these events, not just in the next year but for all the remaining years of his or her life, is a formidably complex and probably impossible task. Markov model advocates tacitly admit this by simply doing away with the whole sticky issue of assessing patient values, notwithstanding that many studies have demonstrated substantial variability in patient preferences and have therefore emphasized the need to assess these preferences on an individual basis.2-4 Even in the absence of explicit value assessment, these other models are often extremely complex.1 In this article I have sought above all to achieve an approach that both explicitly incorporates patient values and is sufficiently simple to be workable at the bedside. The standard gamble method used here, which is well accepted in the decision analysis literature, makes this possible.
